<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00120575</url>
  </required_header>
  <id_info>
    <org_study_id>BMT CVVH</org_study_id>
    <nct_id>NCT00120575</nct_id>
  </id_info>
  <brief_title>Hemofiltration for Respiratory Failure After Bone Marrow Transplantation</brief_title>
  <official_title>Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      For children undergoing bone marrow transplantation, respiratory failure is a devastating&#xD;
      complication, with mortality expectations well above 60%. The researchers have devised a&#xD;
      novel strategy that may greatly improve survival. Hemofiltration, a continuous form of&#xD;
      dialysis, was designed as a therapy for critically ill patients with kidney failure. A&#xD;
      semi-permeable membrane removes plasma water and solutes (up to about 35,000 Daltons&#xD;
      molecular weight). The researchers have treated immuno-compromised children with respiratory&#xD;
      failure with hemofiltration. Many inflammatory molecules are of a size well below the limit&#xD;
      of the filter. Hemofiltration might remove a critical amount of this inflammatory material,&#xD;
      attenuating the unregulated inflammatory response that is central to the development of&#xD;
      respiratory failure and progression to multiple organ failure and death. The researchers are&#xD;
      conducting a multi-center trial of early continuous hemofiltration for respiratory failure in&#xD;
      children following bone marrow transplantation. The researchers will analyze blood and&#xD;
      ultrafiltrate using sensitive proteomic methods to detect several inflammatory biochemicals&#xD;
      known to be active in this disease, looking for evidence that early active hemofiltration&#xD;
      alters the inflammatory response. The researchers will test whether 'early' hemofiltration&#xD;
      produces greater survival from respiratory failure in this vulnerable population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For children undergoing bone marrow transplantation, respiratory failure carries mortality&#xD;
      expectations well above 60%. The researchers have published preliminary evidence that&#xD;
      continuous hemofiltration may greatly improve survival, if filtration is begun when the child&#xD;
      first fulfills clinical criteria for ARDS. This is a departure from standard practice, as&#xD;
      hemofiltration is usually begun later in the course (if at all) when multiple organ failure&#xD;
      is entrenched. Hemofiltration, a 'renal replacement therapy' for critically ill patients, is&#xD;
      a slow, continuous process in which a semi-permeable membrane removes plasma water and&#xD;
      solutes (up to about 35 kiloDaltons). Many cytokine and chemokine molecules are smaller than&#xD;
      the molecular weight limit of the filter; hemofiltration might remove a critical amount,&#xD;
      attenuating the unregulated inflammatory response responsible for respiratory failure and&#xD;
      progression to multiple organ failure and death. The researchers will conduct a multi-center&#xD;
      randomized trial assessing the effect of hemofiltration on survival from respiratory after&#xD;
      bone marrow (or more precisely, hematopoietic stem cell) transplantation. The researchers&#xD;
      will perform sensitive proteomic assays of serum and ultrafiltrate, to detect the presence of&#xD;
      cytokines and chemokines known to be active in idiopathic pneumonia syndrome. Resulting&#xD;
      profiles will constitute a uniquely complex description of ultrafiltrate and may provide&#xD;
      evidence for modulation of immune function by hemofiltration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2005</start_date>
  <completion_date>September 2008</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>PELOD organ failure score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of ventilator-free days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospitalization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional outcome score</measure>
  </secondary_outcome>
  <enrollment>112</enrollment>
  <condition>Bone Marrow Transplantation</condition>
  <condition>Respiratory Insufficiency</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hemofiltration</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  hematopoietic stem cell recipient&#xD;
&#xD;
          -  respiratory failure fulfilling ARDS criteria&#xD;
&#xD;
          -  mechanical ventilation (invasive / non-invasive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  extracorporeal membrane oxygenation (ECMO)&#xD;
&#xD;
          -  predominance of congestive heart failure&#xD;
&#xD;
          -  code status: a patient must be willing to accept invasive mechanical ventilation if&#xD;
             clinically indicated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph V DiCarlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph V DiCarlo, MD</last_name>
    <phone>(650) 497-8850</phone>
    <email>jdicarlo@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital and Research Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vivienne Newman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vivienne Newman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta @ Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Fortenberry, MD</last_name>
    </contact>
    <investigator>
      <last_name>James Fortenberry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ira Cheifetz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ira Cheifetz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vinay Nadkarni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vinay Nadkarni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Skippen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Gordon Krahn</last_name>
    </contact_backup>
    <investigator>
      <last_name>Peter Skippen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Hummler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Helmut Hummler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quen Mok, MB BS</last_name>
    </contact>
    <investigator>
      <last_name>Quen Mok, MB BS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>DiCarlo JV, Alexander SR, Agarwal R, Schiffman JD. Continuous veno-venous hemofiltration may improve survival from acute respiratory distress syndrome after bone marrow transplantation or chemotherapy. J Pediatr Hematol Oncol. 2003 Oct;25(10):801-5.</citation>
    <PMID>14528104</PMID>
  </reference>
  <reference>
    <citation>Di Carlo JV, Alexander SR. Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs. 2005 Aug;28(8):777-86. Review.</citation>
    <PMID>16211527</PMID>
  </reference>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>July 11, 2005</study_first_submitted>
  <study_first_submitted_qc>July 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2005</study_first_posted>
  <last_update_submitted>December 1, 2006</last_update_submitted>
  <last_update_submitted_qc>December 1, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2006</last_update_posted>
  <keyword>Hemofiltration</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

